首页> Antimicrobial agents and chemotherapy.> Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015)

Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015)

导出原文传递

翻译打印收藏纠错

作者： Pfaller, Michael A. ^[1] ; Mendes, Rodrigo E. ^[2] ; Streit, Jennifer M. ; Hogan, Patricia A. ; Flamm, Robert K.

作者单位： Pfizer Inc, Collegeville, PA USA ^[1] JMI Labs, North Liberty, IA 52317 USA ^[2]

关键词 LEADER linezolid oxazolidinones

发布时间 2018-02-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Antimicrobial agents and chemotherapy.

2017年61卷7期

e00609-17-e00609-17页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Antimicrobial agents and chemotherapy.

2017年61卷7期

e00609-17-e00609-17页

检索历史清除

Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015)

Antimicrobial agents and chemotherapy.

相似文献

Antimicrobial agents and chemotherapy.

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015)

Antimicrobial agents and chemotherapy.

相似文献

Antimicrobial agents and chemotherapy.

相关期刊

检索历史清除